

In the Claims

1-59 (canceled).

60 (new). A method of treating a condition in an animal mediated by an immune response which comprises administering to said animal an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD154, LFA-1, CD80, CD86 and ICAM-1, and a non-cellular protein antigen to generate a population of regulatory T-lymphocytes.

61 (new). The method of claim 60, further comprising reactivating said population of regulatory T-lymphocytes by further administration to the animal of the non-cellular protein antigen and transplanting said organ or tissue whilst said population of regulatory T-lymphocytes is activated.

62 (new). The method of claim 60, wherein the condition is an autoimmune condition or rejection of a transplanted organ or tissue.

63 (new). The method of claim 62, wherein the autoimmune condition is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, insulin dependent diabetes mellitus and inflammatory bowel disease.

64 (new). The method of claim 60, wherein the animal is also treated with an immunosuppressive agent or other adjunctive therapy.

65 (new). The method of claim 64, wherein the animal is treated with a sub-therapeutic dose of an immunosuppressive agent.

66 (new). The method of claim 65, wherein the other adjunctive therapy comprises treatment with an anti-CD8 antibody.

67 (new). The method of claim 60, wherein the animal is a human.

68 (new). The method of claim 60, wherein the antibody is an anti-CD4 antibody.

69 (new). The method of claim 68, wherein the antibody is a non-depleting anti-CD4 antibody.

70 (new). The method of claim 60, wherein the non-cellular protein antigen is administered parenterally.

71 (new). The method of claim 60, wherein the antibody is administered to the animal in a dose in the range 0.25 to 25mg/kg.

72 (new). The method of claim 60, wherein the antibody is administered to the animal in a dose in the range 5 to 10mg/kg.

73 (new). The method of claim 71, wherein 1, 2, 3, 4, or 5 such doses are administered to the animal.

74 (new). The method of claim 72, wherein 1, 2, 3, 4, or 5 such doses are administered to the animal.

75 (new). The method of claim 60, wherein the non-cellular protein antigen is selected from the group consisting of human gamma globulin, equine gamma globulin and ovalbumin.

76 (new). An *ex vivo* method for generating a population of regulatory T lymphocytes comprising culturing T cells with an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD154, LFA-1, CD80, CD86 and ICAM-1 in the presence of cells that present either alloantigen or a non-cellular protein antigen.

77 (new). The method of claim 76, wherein the non-cellular protein antigen is selected from the group consisting of human gamma globulin, equine gamma globulin and ovalbumin.

78 (new). The method of claim 76, wherein the T cells are taken from a recipient animal and the cells that present alloantigen are either cells taken from a donor animal or cells pulsed with antigen taken from a donor animal.

79 (new). A method of suppressing rejection of an organ or tissue transplant in a recipient animal comprising the following steps:

- (a) taking a sample of T cells from the recipient animal;
- (b) taking a sample of alloantigen from a donor animal, said donor animal being the source of the organ or tissue being transplanted;
- (c) exposing said sample of T cells to said sample of alloantigen in the presence of an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD154, LFA-1, CD80, CD86 and ICAM-1 to generate a population of regulatory T lymphocytes;
- (d) administering to the recipient animal said population of regulatory T-lymphocytes *ex vivo*.

80 (new). The method of claim 79, wherein said population of regulatory T-lymphocytes is administered to the recipient animal after transplant of an organ or tissue.

81 (new). The method of claim 79, wherein the animal is a human.

82 (new). The method of claim 79, wherein the antibody is an anti-CD4 antibody.

83 (new). The method of claim 82, wherein the antibody is a non-depleting anti-CD4 antibody.

84 (new). Regulatory T lymphocytes produced by the method of claim 76.